M 1001

Drug Profile

M 1001

Alternative Names: M-1001; MEDICA M1001

Latest Information Update: 25 Jul 2016

Price : $50

At a glance

  • Originator SyndromeX
  • Class Antihyperlipidaemics
  • Mechanism of Action AMP activated protein kinase modulators; FOXO1 protein expression modulators; Hepatocyte nuclear factor 4 modulators; Mitochondrial permeability transition pore modulators; STAT3 transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyslipidaemias

Most Recent Events

  • 25 Jul 2016 Phase-II clinical trials in Dyslipidaemias in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top